Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06830096 · ClinicalTrials.gov registry record · NA
Role of KATP Channel Loss in Type 2 Diabetes
A NA study of Obesity and Type 2 Diabetes, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06830096 is a NA study of Obesity and Type 2 Diabetes that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 40 participants, below the 81-participant average among 5 other Obesity and Type 2 Diabetes trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06830096, a NA study of Obesity and Type 2 Diabetes, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Insulin is a hormone that is made by β-cells in the pancreas and when released into the bloodstream helps control blood sugar levels. Insulin release is regulated by electrical activity in the β-cell which is generated by the ATP-sensitive potassium (KATP) channel. While reduced KATP activity is associated with increased insulin secretion, animals lacking KATP exhibit reduced secretion. This crossover from hypersecretion to undersecretion with KATP loss mirrors insulin secretion during type 2 diabetes. Intriguingly, evidence from cell and animal models suggest that chronically stimulated β-cells can lose KATP revealing a possible role for KATP loss in the failure of insulin secretion and poor control of blood sugar observed in type 2 diabetes. This study will therefore examine insulin responses following ingestion of a single dose of a sulfonylurea called glipizide that inhibits KATP channels in people with and without type 2 diabetes. The goal is to determine whether KATP channel activity is reduced during type 2 diabetes progression.
Conditions Studied
Interventions
- DRUG 10 mg glipizide ingestion
Study Locations (1)
Missouri
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-03-07 |
| Est. Completion | 2026-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06830096
The ClinicalTrials.gov registry entry for NCT06830096 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 81-participant average among 5 other Obesity and Type 2 Diabetes trials with a reported enrollment target (51% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity and Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which 10 mg glipizide ingestion is the first listed.
NCT06830096 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06830096 about?
NCT06830096 is a clinical study titled "Role of KATP Channel Loss in Type 2 Diabetes". Insulin is a hormone that is made by β-cells in the pancreas and when released into the bloodstream helps control blood sugar levels. Insulin release is regulated by electrical activity in the β-cell which is generated by the ATP-sensitive potassium (KATP) channel. While reduced KATP activity is ass...
What is the current status of trial NCT06830096?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-03-07. Estimated completion is 2026-07-01.
What conditions does trial NCT06830096 study?
This clinical trial studies the following conditions: Obesity and Type 2 Diabetes.
What interventions are being tested in trial NCT06830096?
The interventions under investigation include: 10 mg glipizide ingestion (DRUG).
Who is sponsoring clinical trial NCT06830096?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06830096 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity and Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mobile Regulation of Craving Training (mROC-T) to Improve Dietary Intake in Rural Adolescent Girls
RECRUITING · NA
-
Effects of HIIT vs. TRE on Type 2 Diabetes Risk
RECRUITING · NA
-
Adapting and Assessing the Feasibility of a Telehealth Diabetes Prevention Program for Hispanic Adolescents
RECRUITING · NA
-
Investigating Metabolic and Psychological Adaptations in a Clinical Trial
ACTIVE NOT RECRUITING · NA
-
Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.